| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-212 |
Sentence |
denotes |
Effect of high-intensity exercise on cardiorespiratory fitness, cardiovascular disease risk and disease activity in patients with inflammatory joint disease: protocol for the ExeHeart randomised controlled trial. |
| T2 |
213-226 |
Sentence |
denotes |
INTRODUCTION: |
| T3 |
227-402 |
Sentence |
denotes |
Inflammatory joint disease (IJD) is associated with increased risk of cardiovascular disease (CVD) fostered by systemic inflammation and a high prevalence of CVD risk factors. |
| T4 |
403-529 |
Sentence |
denotes |
Cardiorespiratory fitness (CRF) is an important health parameter and CRF-measures are advocated in routine health evaluations. |
| T5 |
530-679 |
Sentence |
denotes |
CRF associates with CVD risk, and exercise modalities such as high intensity interval training (HIIT) can increase CRF and mitigate CVD risk factors. |
| T6 |
680-786 |
Sentence |
denotes |
In IJD, exercise is rarely used in CVD risk management and the cardioprotective effect of HIIT is unclear. |
| T7 |
787-906 |
Sentence |
denotes |
Furthermore, the clinical applicability of HIIT to primary care settings is largely unknown and warrants investigation. |
| T8 |
907-995 |
Sentence |
denotes |
The primary aim is to assess the effect of a HIIT programme on CRF in patients with IJD. |
| T9 |
996-1195 |
Sentence |
denotes |
Second, we will evaluate the effect of HIIT on CVD risk and disease activity in patients with IJD, feasibility of HIIT in primary care and validity of non-exercise algorithms to detect change in CRF. |
| T10 |
1196-1217 |
Sentence |
denotes |
METHODS AND ANALYSIS: |
| T11 |
1218-1276 |
Sentence |
denotes |
ExeHeart is a single-blinded, randomised controlled trial. |
| T12 |
1277-1394 |
Sentence |
denotes |
Sixty patients with IJD will be recruited from the Preventive Cardio-Rheuma clinic at Diakonhjemmet Hospital, Norway. |
| T13 |
1395-1593 |
Sentence |
denotes |
Patients will be assigned to receive standard care (relevant lifestyle advice and cardio-preventive medication) or standard care plus a 12-week HIIT intervention by physiotherapists in primary care. |
| T14 |
1594-1657 |
Sentence |
denotes |
HIIT sessions will be prescribed at 90%-95% of peak heart rate. |
| T15 |
1658-1942 |
Sentence |
denotes |
Outcomes include CRF (primary outcome), CVD risk factors, anthropometric measures, disease activity and patient-reported outcomes related to pain, fatigue, disease, physical activity and exercise and will be assessed at baseline, 3 months (primary endpoint) and 6 months postbaseline. |
| T16 |
1943-1968 |
Sentence |
denotes |
ETHICS AND DISSEMINATION: |
| T17 |
1969-2080 |
Sentence |
denotes |
Ethical approval has been obtained from the Regional Committee for Medical and Health Research Ethics (201227). |
| T18 |
2081-2147 |
Sentence |
denotes |
Participants are required to sign a written informed consent form. |
| T19 |
2148-2276 |
Sentence |
denotes |
Results will be discussed with patient representatives, submitted to peer-reviewed journals and presented at relevant platforms. |
| T20 |
2277-2316 |
Sentence |
denotes |
TRIAL REGISTRATION NUMBER: NCT04922840. |
| T1 |
0-212 |
Sentence |
denotes |
Effect of high-intensity exercise on cardiorespiratory fitness, cardiovascular disease risk and disease activity in patients with inflammatory joint disease: protocol for the ExeHeart randomised controlled trial. |
| T2 |
213-226 |
Sentence |
denotes |
INTRODUCTION: |
| T3 |
227-402 |
Sentence |
denotes |
Inflammatory joint disease (IJD) is associated with increased risk of cardiovascular disease (CVD) fostered by systemic inflammation and a high prevalence of CVD risk factors. |
| T4 |
403-529 |
Sentence |
denotes |
Cardiorespiratory fitness (CRF) is an important health parameter and CRF-measures are advocated in routine health evaluations. |
| T5 |
530-679 |
Sentence |
denotes |
CRF associates with CVD risk, and exercise modalities such as high intensity interval training (HIIT) can increase CRF and mitigate CVD risk factors. |
| T6 |
680-786 |
Sentence |
denotes |
In IJD, exercise is rarely used in CVD risk management and the cardioprotective effect of HIIT is unclear. |
| T7 |
787-906 |
Sentence |
denotes |
Furthermore, the clinical applicability of HIIT to primary care settings is largely unknown and warrants investigation. |
| T8 |
907-995 |
Sentence |
denotes |
The primary aim is to assess the effect of a HIIT programme on CRF in patients with IJD. |
| T9 |
996-1195 |
Sentence |
denotes |
Second, we will evaluate the effect of HIIT on CVD risk and disease activity in patients with IJD, feasibility of HIIT in primary care and validity of non-exercise algorithms to detect change in CRF. |
| T10 |
1196-1217 |
Sentence |
denotes |
METHODS AND ANALYSIS: |
| T11 |
1218-1276 |
Sentence |
denotes |
ExeHeart is a single-blinded, randomised controlled trial. |
| T12 |
1277-1394 |
Sentence |
denotes |
Sixty patients with IJD will be recruited from the Preventive Cardio-Rheuma clinic at Diakonhjemmet Hospital, Norway. |
| T13 |
1395-1593 |
Sentence |
denotes |
Patients will be assigned to receive standard care (relevant lifestyle advice and cardio-preventive medication) or standard care plus a 12-week HIIT intervention by physiotherapists in primary care. |
| T14 |
1594-1657 |
Sentence |
denotes |
HIIT sessions will be prescribed at 90%-95% of peak heart rate. |
| T15 |
1658-1942 |
Sentence |
denotes |
Outcomes include CRF (primary outcome), CVD risk factors, anthropometric measures, disease activity and patient-reported outcomes related to pain, fatigue, disease, physical activity and exercise and will be assessed at baseline, 3 months (primary endpoint) and 6 months postbaseline. |
| T16 |
1943-1968 |
Sentence |
denotes |
ETHICS AND DISSEMINATION: |
| T17 |
1969-2080 |
Sentence |
denotes |
Ethical approval has been obtained from the Regional Committee for Medical and Health Research Ethics (201227). |
| T18 |
2081-2147 |
Sentence |
denotes |
Participants are required to sign a written informed consent form. |
| T19 |
2148-2276 |
Sentence |
denotes |
Results will be discussed with patient representatives, submitted to peer-reviewed journals and presented at relevant platforms. |
| T20 |
2277-2316 |
Sentence |
denotes |
TRIAL REGISTRATION NUMBER: NCT04922840. |